🚨 A personalized cancer vaccine just delivered Phase III success!
🔥 INTerpath-001 | #ESMO26
In resected high-risk melanoma, intismeran + pembrolizumab vs pembrolizumab alone:
📉 42% lower recurrence/death risk (HR 0.58)
📊 24-month RFS: 82.2% vs 70.0%
🎯 DMFS: HR 0.62 (P=0.002)
⚠️ More injection-related AEs, largely low-grade.
💡 Could personalized mRNA vaccines redefine adjuvant melanoma therapy?
@my_esmo @ESMO_open @ASCO @oncoalert
#Melanoma #CancerVaccine
165 views · 2 likes · 1 repost · 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org🚨 ESMO 2026: 15 Trials That Could Change Oncology Practice! From personalized cancer vaccines and bispecific antibodies to next-generation ADCs, major results are coming. 🔥 My Top 15 to Watch: 1. INTerpath-001 | Melanoma 2. SAFFRON | EGFR+ NSCLC 3. Krascendo 1 | KRAS G12C NSCLC 4. DeLLphi-305 | ES-SCLC 5. HARMONi-GI1 | Biliary 6. VOLGA | Bladder 7. DASL-HiCaP | Prostate 8. NATALEE | Breast 9. TRIO-US B-12 TALENT | Breast 10. ENERGIZE | Bladder 11. CLARITY-Gastric 01 | Gastric 12. KEYNOTE-C93 | Endometrial 13. KEYNOTE-B49 | Breast 14. LITESPARK-011 | RCC 15. SigVie-002 | NSCLC 📊 The big question: Which trials will deliver meaningful survival benefits and redefine standards of care? Not every positive trial is practice-changing. 👨⚕️ Oncologists, which trial are you watching most closely? #ESMO26 #Oncology #CancerResearch @ASCO @oncoalert @myesmo @esmo_open在 X 查看被引用的帖子
Source: Dr Rishabh Jain · x.com